These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11111926)

  • 1. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials.
    Pizza M; Giuliani MM; Fontana MR; Douce G; Dougan G; Rappuoli R
    Int J Med Microbiol; 2000 Oct; 290(4-5):455-61. PubMed ID: 11111926
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.
    Rappuoli R; Pizza M; Douce G; Dougan G
    Immunol Today; 1999 Nov; 20(11):493-500. PubMed ID: 10529776
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholera toxin and related enterotoxins as potent immune modulators.
    Hirst TR; Nashar TO; Pitman RS; Williams NA
    Symp Ser Soc Appl Microbiol; 1998; 27():26S-34S. PubMed ID: 9750359
    [No Abstract]   [Full Text] [Related]  

  • 5. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.
    Simmons CP; Mastroeni P; Fowler R; Ghaem-maghami M; Lycke N; Pizza M; Rappuoli R; Dougan G
    J Immunol; 1999 Dec; 163(12):6502-10. PubMed ID: 10586042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADP-ribosylating enterotoxins as vaccine adjuvants.
    Lycke N; Lebrero-Fernández C
    Curr Opin Pharmacol; 2018 Aug; 41():42-51. PubMed ID: 29702466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.
    Bagley KC; Abdelwahab SF; Tuskan RG; Lewis GK
    Infect Immun; 2003 Dec; 71(12):6850-6. PubMed ID: 14638772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.
    Pizza M; Giuliani MM; Fontana MR; Monaci E; Douce G; Dougan G; Mills KH; Rappuoli R; Del Giudice G
    Vaccine; 2001 Mar; 19(17-19):2534-41. PubMed ID: 11257389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches.
    Anosova NG; Chabot S; Shreedhar V; Borawski JA; Dickinson BL; Neutra MR
    Mucosal Immunol; 2008 Jan; 1(1):59-67. PubMed ID: 19079161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.
    Williams NA; Hirst TR; Nashar TO
    Immunol Today; 1999 Feb; 20(2):95-101. PubMed ID: 10098329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the immune response by the cholera-like enterotoxins.
    Plant A; Williams NA
    Curr Top Med Chem; 2004; 4(5):509-19. PubMed ID: 14965302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune modulation by the cholera-like enterotoxins.
    Salmond RJ; Luross JA; Williams NA
    Expert Rev Mol Med; 2002 Oct; 4(21):1-16. PubMed ID: 14585161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholera-like enterotoxins and Regulatory T cells.
    Basset C; Thiam F; Martino CD; Holton J; Clements JD; Kohli E
    Toxins (Basel); 2010 Jul; 2(7):1774-95. PubMed ID: 22069660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.
    Bagley KC; Abdelwahab SF; Tuskan RG; Fouts TR; Lewis GK
    Infect Immun; 2002 Oct; 70(10):5533-9. PubMed ID: 12228279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin.
    Millar DG; Hirst TR; Snider DP
    Infect Immun; 2001 May; 69(5):3476-82. PubMed ID: 11292779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity.
    Lycke N; Tsuji T; Holmgren J
    Eur J Immunol; 1992 Sep; 22(9):2277-81. PubMed ID: 1381311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects.
    Sánchez J; Holmgren J
    Cell Mol Life Sci; 2008 May; 65(9):1347-60. PubMed ID: 18278577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.